These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 16103880

  • 1. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
    Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J.
    Oncogene; 2005 Nov 24; 24(53):7859-68. PubMed ID: 16103880
    [Abstract] [Full Text] [Related]

  • 2. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
    Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J.
    Oncogene; 2002 Oct 10; 21(46):7011-26. PubMed ID: 12370823
    [Abstract] [Full Text] [Related]

  • 3. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
    Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J.
    FASEB J; 2005 Nov 10; 19(13):1884-6. PubMed ID: 16166198
    [Abstract] [Full Text] [Related]

  • 4. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
    Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.
    J Cell Sci; 2004 Apr 15; 117(Pt 10):2037-49. PubMed ID: 15054110
    [Abstract] [Full Text] [Related]

  • 5. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
    Noblitt LW, Bangari DS, Shukla S, Mohammed S, Mittal SK.
    Cancer Gene Ther; 2005 Jan 15; 12(1):46-53. PubMed ID: 15486559
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.
    Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A, Chen J.
    J Cell Sci; 2008 Feb 01; 121(Pt 3):358-68. PubMed ID: 18198190
    [Abstract] [Full Text] [Related]

  • 7. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.
    Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P.
    Cancer Res; 2009 Mar 01; 69(5):2072-81. PubMed ID: 19244130
    [Abstract] [Full Text] [Related]

  • 8. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
    Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B.
    Cancer Res; 2006 Jul 15; 66(14):7050-8. PubMed ID: 16849550
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 10. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D.
    Cancer Res; 2006 Feb 15; 66(4):2028-37. PubMed ID: 16489002
    [Abstract] [Full Text] [Related]

  • 11. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
    Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J.
    Cancer Res; 2006 Nov 01; 66(21):10315-24. PubMed ID: 17079451
    [Abstract] [Full Text] [Related]

  • 12. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
    Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, Hendrix MJ.
    Cancer Res; 2001 Apr 15; 61(8):3250-5. PubMed ID: 11309274
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N.
    Cancer; 2007 Oct 01; 110(7):1469-77. PubMed ID: 17685394
    [Abstract] [Full Text] [Related]

  • 14. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
    Pratt RL, Kinch MS.
    Mol Cancer Res; 2003 Dec 01; 1(14):1070-6. PubMed ID: 14707290
    [Abstract] [Full Text] [Related]

  • 15. Differential EphA2 epitope display on normal versus malignant cells.
    Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS.
    Cancer Res; 2003 Nov 15; 63(22):7907-12. PubMed ID: 14633720
    [Abstract] [Full Text] [Related]

  • 16. A conditional feedback loop regulates Ras activity through EphA2.
    Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F.
    Cancer Cell; 2005 Aug 15; 8(2):111-8. PubMed ID: 16098464
    [Abstract] [Full Text] [Related]

  • 17. EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
    Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS.
    Cancer Res; 2001 Mar 01; 61(5):2301-6. PubMed ID: 11280802
    [Abstract] [Full Text] [Related]

  • 18. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
    Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS.
    Cancer Res; 2002 May 15; 62(10):2840-7. PubMed ID: 12019162
    [Abstract] [Full Text] [Related]

  • 19. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
    Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS.
    Mol Cancer Res; 2007 Mar 15; 5(3):283-93. PubMed ID: 17374733
    [Abstract] [Full Text] [Related]

  • 20. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
    Taddei ML, Parri M, Angelucci A, Bianchini F, Marconi C, Giannoni E, Raugei G, Bologna M, Calorini L, Chiarugi P.
    Mol Cancer Res; 2011 Feb 15; 9(2):149-60. PubMed ID: 21205836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.